← All peptidesPDA-V1 attestation Citations
verifiedBioGate · GREENGrade B
Teriparatide (PTH 1-34, Forteo)
SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNFDaily SC PTH(1-34); intermittent exposure activates PTH1R for net bone formation, increasing BMD and reducing fracture risk.
recombinant N-terminal PTH(1-34)
MW
4117.72
Length
34aa
Posterior
61.5%
Structural preview · ESMFold-2 mockdeterministic per sequence
Backbone preview · recombinant N-terminal PTH(1-34)
Cryptographic chain of custody.
- Outer PDA hash
- Inputs hash
- Merkle root
- TEE attestation
- Protocol version
- PDA-V1
- Source
- peptide-md
- Model version
- structure-fm-2026.04
- Candidates emitted
- 5
- Signed
- 2026-04-21T08:14:33Z
Verifiable in your browser at /verifier with
@peptide-md/verifier.Real-world evidence
Cohort-attested outcomes.
Cohorts
4
Participants
328
Mean Δ
-1.94
Δ HRV ms (8-week) · 95% CI [-2.48, -1.4]
IPNFT · Molecule IPNFT V2Solana
Teriparatide (PTH 1-34, Forteo)
512a8d…f14c2aRoyalty cascade
6.81%
Holders
263
Royalty cascade routes lab fees, licensing, and OEA-attested cohort revenues back to holders, the cohort treasury, and the originating researchers in a 60 / 25 / 15 split.
Source literature.
Grade A2001 · N Engl J Med
Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women
Neer RM et al.